227 related articles for article (PubMed ID: 12168946)
21. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
[TBL] [Abstract][Full Text] [Related]
22. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
Helm CW; Randall-Whitis L; Martin RS; Metzinger DS; Gordinier ME; Parker LP; Edwards RP
Gynecol Oncol; 2007 Apr; 105(1):90-6. PubMed ID: 17173957
[TBL] [Abstract][Full Text] [Related]
23. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
van de Vaart PJ; van der Vange N; Zoetmulder FA; van Goethem AR; van Tellingen O; ten Bokkel Huinink WW; Beijnen JH; Bartelink H; Begg AC
Eur J Cancer; 1998 Jan; 34(1):148-54. PubMed ID: 9624250
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
26. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells: results of an in vitro study.
Muller M; Chérel M; Dupré PF; Gouard S; Collet M; Classe JM
Eur Surg Res; 2011; 46(3):139-47. PubMed ID: 21372578
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
de Bree E; Rosing H; Filis D; Romanos J; Melisssourgaki M; Daskalakis M; Pilatou M; Sanidas E; Taflampas P; Kalbakis K; Beijnen JH; Tsiftsis DD
Ann Surg Oncol; 2008 Apr; 15(4):1183-92. PubMed ID: 18239973
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Molucon-Chabrot C; Isambert N; Benoit L; Zanetta S; Fraisse J; Guilland JC; Royer B; Monin-Baroille P; Flesch M; Fargeot P; Coudert B; Mayer F; Fumoleau P; Chauffert B
Anticancer Drugs; 2006 Nov; 17(10):1211-7. PubMed ID: 17075321
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study.
Jehn CF; Boulikas T; Kourvetaris A; Possinger K; Lüftner D
Anticancer Res; 2007; 27(1A):471-5. PubMed ID: 17352269
[TBL] [Abstract][Full Text] [Related]
31. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma.
Lentz SS; Miller BE; Kucera GL; Levine EA
Gynecol Oncol; 2007 Jul; 106(1):207-10. PubMed ID: 17498782
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
33. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.
Raspagliesi F; Kusamura S; Campos Torres JC; de Souza GA; Ditto A; Zanaboni F; Younan R; Baratti D; Mariani L; Laterza B; Deraco M
Eur J Surg Oncol; 2006 Aug; 32(6):671-5. PubMed ID: 16621425
[TBL] [Abstract][Full Text] [Related]
34. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Covens A; Blessing J; Bender D; Mannel R; Morgan M;
Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
[TBL] [Abstract][Full Text] [Related]
35. [Intraperitoneal administration of anti-cancer drug with cisplatinum (CDDP)].
Hirahata S; Kumai K; Hurukawa T; Shimada A; Shibata S; Aizawa K; Matsui H; Takahara T; Shimizu H; Hukase T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1555-60. PubMed ID: 2389948
[TBL] [Abstract][Full Text] [Related]
36. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Steller MA; Egorin MJ; Trimble EL; Bartlett DL; Zuhowski EG; Alexander HR; Dedrick RL
Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.
Sugarbaker PH; Stuart OA; Carmignani CP
Cancer Chemother Pharmacol; 2006 May; 57(5):703-8. PubMed ID: 16096789
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: II. High-dose cisplatin is well tolerated by the native lung tissue.
Franke UF; Wittwer T; Kaluza M; Albert M; Becker V; Roskos M; Lessel M; Wahlers T
Eur J Cardiothorac Surg; 2004 Oct; 26(4):800-6. PubMed ID: 15450576
[TBL] [Abstract][Full Text] [Related]
39. Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb: pharmacokinetics, thermal dose, toxicity, and feasibility.
Abe S; Tokizaki T; Miki Y; Tateishi A; Ogawa K; Nakano H; Matsushita T
Cancer Chemother Pharmacol; 2005 Jul; 56(1):55-62. PubMed ID: 15791455
[TBL] [Abstract][Full Text] [Related]
40. [Chemotherapy in malignant gynecologic tumors using intraperitoneal catheter with a subcutaneous reservoir].
Shimizu A; Kimura T; Funatsu M; Hada Y; Araki H; Notake Y
Gan To Kagaku Ryoho; 1991 Aug; 18(11):1795-9. PubMed ID: 1877820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
